News & Events
Wednesday September 05, 2018
Live Audio Webcast will be on September 12, 2018 SAN DIEGO, Sept. 5, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Morgan Stanley 16th Annual Global Healthcare Conference at 8:10 a.m. ET on Wednesday, Sept. 12, 2018, in New York City. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at http://www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately on...
Wednesday August 22, 2018
AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
- Study results (ELARIS UF-EXTEND) showed elagolix, in combination with add-back therapy, reduced heavy menstrual bleeding for up to 12 months - Results were consistent with two pivotal Phase 3 studies (ELARIS UF-I and ELARIS UF-II) and no new safety signals were identified - Data from the pivotal studies will be presented at a medical conference later this yearNORTH CHICAGO, Ill., Aug. 22, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that results from the Phase 3 ELARIS UF-EXTEND extension study (MI2-816) showed at month 12 that elagolix (300 mg twice daily), in co...
Wednesday August 15, 2018
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2018 World Congress on Parkinson's Disease and Related Disorders
New Long-Term Analyses Highlight Patient-Reported Outcomes and Patient Satisfaction with INGREZZA for the Treatment of Tardive Dyskinesia Three Analyses from Phase III Study Demonstrate Opicapone Improves Motor Fluctuations in Patients with Parkinson's Disease SAN DIEGO, Aug. 15, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data from its movement disorders programs, including additional long-term results for INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), and data analyses from a Phase III study on opicapone, an investigational treatment for...
Tuesday July 31, 2018
INGREZZA® (valbenazine) Second Quarter Net Product Sales of $96.9 Million with Approximately 16,700 TRx ORILISSA™ (elagolix), the First FDA-Approved Oral Treatment for Moderate to Severe Endometriosis Pain in Over a Decade, Expected to be Launched by AbbVie in August 2018 SAN DIEGO, July 31, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended June 30, 2018, and provided an update on the launch of INGREZZA® (valbenazine), the U.S. Food and Drug Administration (FDA) approval for ORILISSA™ (elagolix), and its clinical development programs. "Neurocrine is making great progress wi...
Tuesday July 24, 2018
AbbVie Receives U.S. FDA Approval of ORILISSA™ (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis
- ORILISSA™ (elagolix) is the first FDA-approved oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade - ORILISSA is available in two oral dosages-150 mg once daily and 200 mg twice daily, taken with or without food - FDA approval is supported by the largest endometriosis Phase 3 study program conducted to date - ORILISSA is expected to be available in U.S. retail pharmacies in early August 2018 NORTH CHICAGO, Ill., July 24, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the U.S. Food and Drug Administration (F...
Wednesday September 12, 2018